Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cells + basiliximab + methylprednisolone + rabbit anti-thymocyte globulin + cyclosporine + mycophenolate mofetil
- Development stage
- Unknown
- Lead developer
- Mario Negri Institute for Pharmacological Research
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A multi-component therapeutic regimen developed by the Mario Negri Institute for Pharmacological Research for use in kidney transplantation. The protocol involves the intravenous infusion of syngeneic, ex-vivo expanded mesenchymal stem cells (MSCs) to induce immunomodulatory effects. This cell therapy is combined with an induction regimen consisting of basiliximab (a monoclonal antibody targeting the IL-2 receptor), low-dose rabbit anti-thymocyte globulin (RATG) for T-cell depletion, and methylprednisolone. Maintenance immunosuppression is provided via low-dose cyclosporine (a calcineurin inhibitor) and mycophenolate mofetil (an antimetabolite). The primary objective of this combination is to establish a pro-tolerogenic environment that may eventually allow for the safe withdrawal of maintenance immunosuppressive drugs in living-related kidney transplant recipients.
- Other names
- MSCs for Renal Transplant Tolerance
02
Targets
GR (Glucocorticoid receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)CN (Calcineurin)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on mesenchymal stem cells + basiliximab + methylprednisolone + rabbit anti-thymocyte globulin + cyclosporine + mycophenolate mofetil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cells + basiliximab + methylprednisolone + rabbit anti-thymocyte globulin + cyclosporine + mycophenolate mofetil.